Al-Mehdi NM Pharmacotherapeutics Flashcards
Autoimmune disorder resulting in loss of presynaptic neuronal VGCCs and impaired ACh release
Lambert-Eaton Syndrome
patient presents with weakness what do you automatically think
muscle weakness
fluctuating muscle weakness sign of
neuromuscular junction problems
AchE in synapse of NMJ allows for what to be recycled
choline
in the spinal cord, NOT NMJ, what prevents GABA release by degrading synaptobrevin
Tetanus toxin
at the NMJ level, what degrades SNAP-25 and syntaxin causing no release of Ach
Botulinum toxin
Nm receptor blockers end in
“curonium”
Nm receptor agonists
succinylcholine
acetylcholine
nicotine
Nm only location in the body
NMJ
autoimmune disease targeting VGKC and increase in Ach release
neuromyotonia
condition where your muscles are unable to relax after contraction
myotonia
NMJ disorders highest prevelance in what populations
younger women and older men
this can lead to myasthenia gravis and targets Nm
Thymoma
this is associated w/ Lambert-Eaton syndrome and targets p/q type VGCC
small cell lung cancer
features include: painless, fluctuating muscle weakness and Ptosis; weakness increases with continued activity
Myasthenia Gravis
other main clinical features include dysarthria and myasthenic sneer
Myasthenia Gravis
defined as the need for ventilator support for respiratory muscle weakness
myasthenic crisis
ocular findings of this include shifting ptosis (from one eye to the other)
Myasthenia Gravis
To diagnose MG:
AChE inhibitors
AChE inhibitors used to diagnose MG:
Neostigmine and Edrophonium